Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this exciting learning session on managing Ph negative Acute lymphoblastic leukemia in adults.
Acute Lymphoblastic Leukemia (ALL) is a cancer of the blood and bone marrow that progresses rapidly without treatment. It can reoccur after being in remission from previous treatment. It has been noted that refractory ALL did not respond to treatment indicating the previous treatments did not kill enough leukemia cells (blasts) to reach complete remission.
Ph-positive ALL is a special type of ALL in which a genetic mutation is observed in the Philadelphia chromosome. In the case of Ph-negative ALL, genetic disparities are also observed and most importantly in Ph neg ALL there is a disproportionate survival rate among the patients.
Managing Ph neg ALL often becomes difficult, however, the procedures of management of Philadelphia chromosome (Ph)–negative acute lymphoblastic leukemia (ALL) have changed dramatically in recent years leading to a positive vibe for the situation.
Therefore, have overall knowledge regarding the management of Ph negative ALL. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Study identifies new target for obesity-related breast cancer
2.
Too Many Kids With Sickle Cell Disease Aren't Getting Appropriate Preventive Care
3.
Zebrafish models offer fast, effective guidance for personalized therapies for kids with high-risk cancer
4.
Home Screening Appeals to Women Facing Healthcare Barriers
5.
Research suggests peer support may lower depression, stress among cancer patients in low-resource settings
1.
Leptomeningeal Carcinomatosis: Symptoms, Causes, and Treatment Options
2.
Exploring the Effects of Radiation Therapy on Cystitis: A Journey to Better Health
3.
Unveiling the Hidden Benefits of Lymphedema Treatment
4.
Understanding the Importance of CA125: A Comprehensive Guide
5.
Hepatocellular Carcinoma: Progress in Detection, Pathogenesis, and Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
3.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
4.
The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
Should We Use DARA Up Front As First-Line Therapy in MM?
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation